Related Experiment Video

Updated: Jun 10, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

The impact of health insurance coverage on pediatric diabetes management

Kupper A Wintergerst1, Krystal M Hinkle, Christopher N Barnes

  • 1Department of Pediatrics, Division of Endocrinology, School of Medicine, University of Louisville, Louisville, KY 40202, USA. kawint01@louisville.edu

Diabetes Research and Clinical Practice
|July 16, 2010
PubMed

Insights

Health insurance type significantly impacts diabetes management and control in children with type 1 diabetes. Private insurance is linked to advanced insulin plans and better glycemic control (HbA1c).

Area of Science:

  • Pediatric Endocrinology
  • Health Services Research
  • Diabetes Management

Background:

  • Health insurance coverage is a critical determinant of healthcare access and quality.
  • Insulin management strategies vary significantly among pediatric patients with type 1 diabetes mellitus (T1DM).
  • Understanding the interplay between insurance, management plans, and glycemic control is essential for improving T1DM outcomes.

Purpose of the Study:

  • To investigate the association between health insurance type (public vs. private) and insulin management plans in pediatric T1DM.
  • To evaluate the impact of insurance coverage and management plans on diabetes control, measured by HbA1c levels.

Main Methods:

  • Retrospective cohort study utilizing medical records from a pediatric endocrinology clinic.
  • Analysis included 701 pediatric patients with T1DM, categorized by insurance type.
  • Insulin administration methods (injections, multiple daily injections [MDI], insulin pumps) and HbA1c levels were assessed.

Main Results:

  • A higher proportion of privately insured patients utilized multiple daily injection (MDI) plans or insulin pumps (58%) compared to publicly insured patients (21%).
  • Privately insured patients using MDI/pumps achieved lower mean HbA1c levels (8.6%) than publicly insured patients (9.8%).
  • Limitations in insulin pen use and glucose test strip availability may hinder MDI/pump adoption among publicly insured youth.

Conclusions:

  • Insurance type is a significant predictor of insulin management plan selection and diabetes control in pediatric T1DM.
  • Disparities in access to advanced insulin therapies and supplies associated with public insurance may contribute to poorer glycemic outcomes.
  • Addressing insurance-related barriers and resource availability is crucial for enhancing diabetes management and control in publicly insured pediatric populations.
Abstract

More Related Videos

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-1906:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...